(Updates Pfizer deal with EU, Moderna-Japan, AstraZeneca deals with U.S., UK, EU; Adds Moderna-Qatar, Australia-Novavax, Argentina-RDIF and Hungary-RDIF deals) Nov 12 (Reuters) - The European Union on Wednesday entered into a deal with Pfizer and BioNTech for the supply of up to 300 million doses of their COVID-19 vaccine candidate, as it tries to catch up with the United States and United Kingdom to secure supplies of experimental vaccines. COUNTRY/REGION COMPANY DEAL TERM NO OF DOSES DELIVERY DATE STORY LINK U.S. Moderna $1.53 bln 100 mln + option for additional Unspecified 400 mln U.S. Pfizer and BioNTech $1.95 bln 100 mln + option for 500 mln By October more U.S. AstraZeneca $1.2 bln 300 mln Expected to begin in October 2020 U.S. Novavax $1.6 bln 100 mln By January 2021 U.S. Johnson & Johnson Over $1 bln 100 mln + 200 mln more under Unspecified subsequent agreement U.S. Sanofi and $2.1 bln 100 mln + option for 500 mln Unspecified GlaxoSmithKline more EU AstraZeneca 750 mln euros for At least 300 mln + 100 mln By end-2020 300 mln doses additional EU Johnson & Johnson Undisclosed 200 mln + 200 mln additional Unspecified EU Sanofi and GlaxoSmithKline 324 mln euros 300 mln Unspecified ($384 mln) EU Moderna In talks 80 mln Unspecified EU CureVac In talks 225 mln + option for 180 mln Unspecified additional EU BioNTech/ Pfizer Not specified Up to 300 mln End of 2020 EU ReiThera In early talks Unspecified Unspecified Italy, AstraZeneca 750 mln euros 300 mln + 100 mln additional Not applicable Germany, the ($843 million) Netherlands and France UK Johnson & Johnson Non-profit basis 30 mln + option for up to 22 Unspecified for emergency use; mln more option to purchase additional doses UK Novavax Not specified 60 mln, and plan for a By early 2021; phase 3 late-stage trial in UK with trial in Q3 govt support UK Valneva "Multi-million 60 mln + 40 mln additional Not Applicable pound" investment UK Sanofi , Financial terms Up to 60 mln Not Applicable GlaxoSmithKline undisclosed UK Pfizer and BioNTech Financial terms 30 mln Not Applicable undisclosed UK AstraZeneca 84 million pounds 100 mln 4 million in 2020. Earlier ($110.40 million) about 30 million doses were expected with initial deliveries by Sept/Oct. 2020 Canada Pfizer and BioNTech Financial details Unspecified Through 2021 undisclosed Canada Moderna Unspecified Unspecified Unspecified Canada Johnson & Johnson Unspecified Up to 38 mln Unspecified Canada AstraZeneca Unspecified Up to 20 mln Unspecified Canada Novavax Unspecified Up to 76 mln Q2 of 2021 Japan Moderna Unspecified 50 mln doses, to be distributed H1 of 2021 by Takeda Japan Pfizer and BioNTech Financial details 120 mln H1 of 2021 undisclosed Japan Johnson & Johnson In talks Not Applicable Not Applicable Japan AstraZeneca Co-production with 120 mln First 30 mln expected by JCR Pharma March 2021 , Daiichi Sankyo Biotech and KM Biologics Japan Novavax Co-production with 250 mln Production is yearly Takeda estimate Europe, Latin Arcturus Therapeutics In talks Not Applicable Not Applicable America and Holdings Inc Southeast Asia Israel Arcturus Therapeutics $275 million Initial 1 mln Not Applicable Israel Moderna Financial terms Not Applicable Not Applicable undisclosed Indonesia Sinovac Biotech Financial terms At least 40 mln By March 2021 undisclosed China AstraZeneca Produced by At least 200 mln By end 2021 Shenzhen Kangtai Biological Products Thailand AstraZeneca Undisclosed Undisclosed Mid-year 2021 Uzbekistan Russia's sovereign fund, Undisclosed Up to 35 mln Unspecified RDIF Egypt RDIF Undisclosed 25 mln Unspecified India RDIF Undisclosed 100 mln Late 2020 Nepal RDIF Undisclosed 25 mln Unspecified Brazil Gamaleya Research Institute Undisclosed Brazil's Bahia state to get 50 To start in November and RDIF mln and will conduct Phase 3 clinical trials Brazil AstraZeneca $356 mln to buy, 100 mln December/January produce vaccine Mexico Gamaleya, RDIF Financial terms 32 mln November 2020 unspecified Mexico, AstraZeneca To produce vaccine 150 mln + up to 250 mln more First half of 2021 Argentina for most of Latin America Qatar Moderna Unspecified Unspecified As soon as vaccine is approved and released Australia Novavax Unspecified 40 mln First half of 2021 Argentina RDIF Unspecified 10 mln Between December and January 2021 Hungary RDIF Unspecified Unspecified To start importing small quantities in December 2020 for final testing and licensing ($1 = 0.8484 euros) ($1 = 0.7609 pounds) (Reporting by Vishwadha Chander, Mrinalika Roy, Manojna Madippatla, Trisha Roy and Manas Mishra in Bengaluru, Rocky Swift in Tokyo; Editing by Sriraj Kalluvila, Shounak Dasgupta, Aditya Soni, Vinay Dwivedi and Ramakrishnan M.)
Our Standards: The Thomson Reuters Trust Principles.